SUMMARY

• The safety and effectiveness of OPSUMIT in pediatric patients have not been established for the treatment of pulmonary arterial hypertension (PAH). An open-label randomized trial in pediatric patients (aged 2 to 17 years) did not demonstrate a clinical benefit of OPSUMIT compared with standard of care in the treatment of PAH.¹ 
• TOMORROW is an ongoing, prospective, multicenter, open-label, randomized, controlled, parallel-group phase 3 study including 148 treatment-naïve pediatric patients aged 2 to 17 years with pulmonary arterial hypertension (PAH) in World Health Organization (WHO) functional class (FC) I-III. Patients were randomized to receive macitentan (n=73) or standard of care (SoC) (n=75).² 
  • The primary endpoint assessed steady-state trough (pre-dose) plasma concentrations of macitentan and its active metabolite, aprocitentan, at week 12.
  • Macitentan and aprocitentan exposure in the pediatric population was consistent with the known profile in adult patients.^2,3 
  • Adverse events (AEs) related to macitentan were reported in 15 (20.8%) patients. Additionally, 26 (36.1%) patients in the macitentan arm and 16 (21.3%) patients in the SoC arm experienced 1 or more serious AEs.
• The phase 3 SERAPHIN and MAESTRO trials allowed inclusion of patients ≥12 years of age.^4,5
  • Analyses of the pediatric subgroup in the SERAPHIN study did not indicate any inconsistent or unexpected efficacy and safety outcomes compared to the overall SERAPHIN population. However, the number of pediatric patients is too small to form a conclusion about the efficacy and safety of macitentan in this population.^4,6
• A search of the scientific literature identified retrospective and prospective studies that evaluated the clinical efficacy and safety of macitentan.^7-10

CLINICAL DATA

Information From the TOMORROW Study

TOMORROW is an ongoing, prospective, multicenter, open-label, randomized, controlled, parallel-group phase 3 study that included 148 treatment-naïve pediatric patients aged 2 to 17 years with PAH in WHO FC I-III.² The primary aim of TOMORROW is to assess the pharmacokinetics (PK) of macitentan in pediatric patients and to provide additional information on efficacy and safety compared to standard of care.² 

Patients were randomized 1:1 to receive macitentan (monotherapy or added to phosphodiesterase type 5 inhibitor [PDE5i] therapy) or SoC. Among the 73 patients randomized to the macitentan arm, 72 received macitentan, while all 75 patients randomized to the SoC arm received standard treatment of ≤2 PAH-specific drugs. Following a disease progression event, background treatment could be escalated in both arms, including the use of intravenous or subcutaneous prostanoids, with patients in the SoC arm having the option to cross over to the macitentan arm.² 

Demographics and baseline characteristics for the study population are presented in Table: Demographics and baseline characteristics.² 

The primary endpoint in TOMORROW assessed the steady-state trough (pre-dose) plasma concentrations of macitentan and its active metabolite, aprocitentan, at week 12.² Macitentan and aprocitentan exposure in the pediatric population was consistent with the known profile in adult patients.^2,3 For macitentan (n=47), the mean concentration was 185 ng/mL (standard deviation [SD] 114.3), with a median of 158 ng/mL (range 6.8-581). For aprocitentan (n=47), the mean concentration was 983 ng/mL (SD 324.1), with a median of 986 ng/mL (range 339-1660).² 

Secondary endpoints include time to first clinical events committee (CEC)-confirmed disease progression, hospitalization for PAH, and death due to PAH; time to first all-cause death; and change from baseline to week 24 in health-related quality of life (HRQoL), along with an assessment of safety and tolerability.² 

The Kaplan-Meier (KM) curves indicated the following hazard ratios (HR): CEC-confirmed disease progression HR 0.828 (95% confidence interval [CI], 0.460 to 1.492), hospitalization for PAH HR 0.912 (95% CI, 0.393 to 2.118), death due to PAH HR 1.53 (95% CI, 0.429 to 5.457), and all-cause death HR 1.171 (95% CI, 0.392 to 3.500). None of these showed statistical significance.² 

HRQoL data were collected for both enrolled pediatric patients and their parents with improvements in both populations observed.² 

The safety profile was consistent with the known profile in adults.^1,2 AEs reported within the macitentan and SoC arms in the safety analysis set are listed in Table: Safety Profile.² 

Pediatric Patients Included in Trials for WHO Group I Pulmonary Hypertension

Information From the SERAPHIN Study

The safety and efficacy of OPSUMIT in the treatment of symptomatic PAH in patients aged ≥12 years was evaluated in a phase 3, randomized, placebo-controlled, event-driven study, SERAPHIN.⁴ Select exclusion criteria included patients <40 kg.¹¹ Of the 742 patients in SERAPHIN, 20 patients (2.7%) aged 12-17 years were enrolled and equally distributed between the 3 treatment groups: 7 (2.8%) in the macitentan 3 mg group, 6 (2.5%) in the OPSUMIT group, and 7 (2.8%) in the placebo group.⁶

The median duration of exposure to macitentan among pediatric patients was 99.6 weeks and 98.7 weeks in the macitentan 3 mg and 10 mg groups, respectively. Of the 20 pediatric patients, 14 (70%) discontinued study treatment prematurely (85.7% in macitentan 3 mg, 50% in OPSUMIT, and 71.4% in placebo group), with disease progression as the main reason for treatment discontinuation.⁶

Baseline characteristics and duration of treatment for the pediatric subgroup are presented in Table: Baseline Characteristics and Mean Treatment Duration for the Pediatric Subgroup (12-17 Years) in the SERAPHIN Study.⁶

The primary endpoint in SERAPHIN was time from treatment initiation to first morbidity or mortality event in all randomized patients up to end of treatment (EOT).⁴ This composite endpoint was defined as death, atrial septostomy, lung transplantation, initiation of intravenous (IV) or subcutaneous (SC) prostanoids, or worsening of PAH (deterioration in 6minute walk distance [6MWD] and worsening of PAH symptoms and need for additional PAH treatment). Secondary endpoints included change from baseline to month 6 in 6MWD and World Health Organization (WHO) functional class (FC), death due to PAH or hospitalization for PAH up to EOT, and all-cause mortality up to EOT and end of study (EOS). Results of the primary and secondary endpoint analyses in the pediatric subgroup are summarized in Table: Summary of Efficacy Endpoint Analyses of the Pediatric Subgroup (12-17 Years) in the SERAPHIN Study.⁶

In the pediatric subgroup of SERAPHIN, worsening of PAH was the most frequently reported adverse event (n=4 in placebo, n=4 in macitentan 3 mg and n=1 in OPSUMIT group).⁶ Right ventricular failure was reported in 3 pediatric patients in the macitentan 3 mg group, 1 pediatric subject in the OPSUMIT group and no pediatric patients in the placebo group. Elevated liver transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] >3 × upper limit of normal (ULN) and total bilirubin >2 × ULN), irrespective of temporal relationship, were reported in 1 pediatric subject in the OPSUMIT group. In this subject, liver enzyme elevations were secondary to ischemic hepatitis combined with hepatitis B. None of the pediatric patients presented with a hemoglobin value below 10 g/dL.⁶

These data are limited to a very small number of patients. Although there were no unexpected or inconsistent efficacy or safety outcomes in these patients compared to the overall SERAPHIN population, these data cannot be used to form any conclusions about the efficacy and safety of macitentan in pediatric patients.⁶

Information From the MAESTRO Study

MAESTRO was a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group, study to evaluate the effects of macitentan on exercise capacity (change in 6MWD from baseline to week 16) in patients with Eisenmenger Syndrome. This study included patients aged ≥12 years. A total of 226 patients were randomized in a 1:1 ratio to receive either once daily OPSUMIT (n=114) or placebo (n=112). MAESTRO did not meet its primary endpoint. Among the patients enrolled in MAESTRO, 15 (6.6%) were aged 12-17 years, 13 of whom were in the OPSUMIT group and 2 of whom were in the placebo group. A separate analysis specific to the pediatric subject subgroup has not been performed.⁵

Information From a Literature Search

Hutter and Pfammatter (2016)⁷  conducted a retrospective analysis of 11 pediatric patients with PAH (age 3.1±7.8 years) who were treated with OPSUMIT daily for a duration of 11.8±10.5 months. Enrolled newborns and young children (9 males, 2 females) were hospitalized for initiation of therapy. A total of 4 patients were switched from sildenafil and 3 patients were switched from bosentan. There was 1 death due to a co-morbid genetic disorder and 1 patient successfully discontinued treatment after 1 year. No safety concerns were reported.

Aypar et al (2020)⁸ conducted a single-center, 24-month prospective study aimed to evaluate the clinical efficacy and safety of the switch from bosentan to macitentan. Twenty-seven patients (10 male and 17 female) were included in the study. Mean age was 21.1±6.3 years (12-36), and weight was 53.1±15.7 kg (26-87). Eight patients (30%) were <18 years old. Macitentan significantly improved 6MWD from baseline (mean: 458±79 m [300-620]) at 6 months (mean: 501±73 m [325-616] +43 m; P<0.05), at 12 months (mean: 514±82 m [330-626] +56 m; P<0.05), and at 24 months (mean: 532±85 m [330-682] +74 m; P<0.05). Although a statistically significant improvement in 6MWD during the first 6 months was observed, an incremental improvement after 6 months was not observed (P>0.05). Macitentan did not significantly change WHO FC, oxygen saturation, and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels (P>0.05). None of the patients experienced anemia, hepatotoxicity, or peripheral edema.

Schweintzger et al (2020)⁹ conducted a single-center, prospective observational study to assess the efficacy and safety of macitentan in pediatric pulmonary hypertension patients. Eighteen patients (10 male and 8 female) with a median age of 8.5 years were included in the study. Nine children were switched from bosentan to macitentan. Macitentan was associated with improvement in the ratio of mPAP to mean systemic arterial pressure with a decrease from a median 62% (min: 30%, max: 87%) to 49% (min: 30%, max: 69%). Additionally, pulmonary vascular resistance index decreased from a median of 7.6 WU·m² (min: 3.3, max: 11.5) to 4.8 WU·m² (min: 2.5, max: 10, P<0.05). 6MWD and New York Heart Association (NYHA) FC did not change significantly. There were no incidents of anemia, peripheral edema or increases in ALT, AST, gamma-glutamyl transferase or bilirubin in the pediatric cohort.

Albinni et al (2023)¹⁰ conducted a single-center, prospective, observational study to assess the mid- and long-term effects of macitentan in children with advanced pulmonary hypertensive vascular disease. Starting doses were administered as a single daily dose and were titrated to target doses, based on body weight. Twenty-four patients (14 male and 10 female), with a mean age of 10.7±7.6 years and a median observation period of 36 months, were enrolled. Macitentan was initiated as monotherapy in 6 patients, dual therapy in 10 patients, and triple therapy in 8 patients. Two patients discontinued the study due to symptomatic peripheral edema in the first 2 weeks after macitentan initiation. A subgroup analysis was also conducted based on patients with (n=10) and without (n=12) PAH-CHD. Within the entire cohort, brain natriuretic peptide (BNP) levels and all echo parameters (right ventricular systolic pressure [RVSP], right ventricular end-diastolic diameter [RVED], TAPSE, pulmonary velocity time integral [VTI], and pulmonary artery acceleration time [PAAT]) improved significantly after 3 months (P≤0.01), whereas at 12 months, significant improvements (P<0.05) persisted only for BNP levels (-16%), VTI (+14%), and PAAT (+11%). On subgroup analysis, patients without PAH-CHD showed significant improvements in BNP levels and all echo parameters at 3 months, whereas at 12 months, significant improvements persisted in all, excluding RVSP and RVED. No significant changes were observed in patients with PAH-CHD at 3 and 12 months.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, DERWENT^® (and/or other resources, including internal/external databases) was conducted on 26 February 2025.